PTPRC and COVID-19: Interestingly, this strategy revealed a CD11clow classical monocytic subset (CD45+ CD116+ CD3ε- CD11clow HLA-DR+ CD14+ CD16-/low CD123-/low) that, in both the Initial and the Replication Cohorts, was consistently enriched in COVID-19 patients relative to healthy controls (Bonferroni-adjusted p = 0.006, Replication Cohort) and was preferentially enriched in the Long-Stay/Died group relative to the Short-Stay group (Bonferroni-adjusted p = 0.076, Replication Cohort) (Figure 3D), though the latter did not achieve statistical significance.